Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

Peripheral T cell lymphoma (PTCL) has a poor prognosis. Overexpression of vascular endothelial growth factor (VEGF) might contribute to the poor prognosis of PTCL and could be the target of novel therapy. The efficacy and safety of recombinant human endostatin (Endostar) in combination with cyclopho...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qunling, Cao, Junning, Xue, Kai, Liu, Xiaojian, Ji, Dongmei, Guo, Ye, Hong, Xiaonan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189703/
https://www.ncbi.nlm.nih.gov/pubmed/28053548
http://dx.doi.org/10.2147/OTT.S117007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189703/
https://www.ncbi.nlm.nih.gov/pubmed/28053548
http://dx.doi.org/10.2147/OTT.S117007

Ejemplares similares